Stock Track | Clarity Pharmaceuticals Soars 5.15% Intraday on Commercial Manufacturing Deal for Cu-64 SAR-bisPSMA

Stock Track

04/15

Clarity Pharmaceuticals Ltd (CU6.AU) saw its stock price soar 5.15% during intraday trading on Wednesday, following the announcement of a significant commercial manufacturing agreement.

The company signed a deal with Nucleus RadioPharma for the manufacturing of Cu-64 SAR-bisPSMA. The agreement covers Nucleus's facility in Rochester, Minnesota, which has a capacity of approximately 50,000 patient doses per year. It also includes a planned site in Spring House, Pennsylvania, targeted to open in 2028 with a capacity of up to 600,000 doses per year.

This manufacturing network is positioned to support the anticipated commercial launch of Cu-64 SAR-bisPSMA following the completion of Phase III trials (AMPLIFY and CLARIFY) and pending FDA New Drug Application approval. The commercial contract took effect on April 14, 2026, the day prior to the stock's movement.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/1184551801"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1184551801\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1184551801?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-15 08:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1184551801","market":"hk","top_or_hot":-1,"title":"Stock Track | Clarity Pharmaceuticals Soars 5.15% Intraday on Commercial Manufacturing Deal for Cu-64 SAR-bisPSMA","media":"Stock Track","content":"<p>Clarity Pharmaceuticals Ltd (CU6.AU) saw its stock price soar 5.15% during intraday trading on Wednesday, following the announcement of a significant commercial manufacturing agreement.</p>\n<p>The company signed a deal with Nucleus RadioPharma for the manufacturing of Cu-64 SAR-bisPSMA. The agreement covers Nucleus's facility in Rochester, Minnesota, which has a capacity of approximately 50,000 patient doses per year. It also includes a planned site in Spring House, Pennsylvania, targeted to open in 2028 with a capacity of up to 600,000 doses per year.</p>\n<p>This manufacturing network is positioned to support the anticipated commercial launch of Cu-64 SAR-bisPSMA following the completion of Phase III trials (AMPLIFY and CLARIFY) and pending FDA New Drug Application approval. The commercial contract took effect on April 14, 2026, the day prior to the stock's movement.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Clarity Pharmaceuticals Soars 5.15% Intraday on Commercial Manufacturing Deal for Cu-64 SAR-bisPSMA</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Clarity Pharmaceuticals Soars 5.15% Intraday on Commercial Manufacturing Deal for Cu-64 SAR-bisPSMA\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-04-15 08:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Clarity Pharmaceuticals Ltd (CU6.AU) saw its stock price soar 5.15% during intraday trading on Wednesday, following the announcement of a significant commercial manufacturing agreement.</p>\n<p>The company signed a deal with Nucleus RadioPharma for the manufacturing of Cu-64 SAR-bisPSMA. The agreement covers Nucleus's facility in Rochester, Minnesota, which has a capacity of approximately 50,000 patient doses per year. It also includes a planned site in Spring House, Pennsylvania, targeted to open in 2028 with a capacity of up to 600,000 doses per year.</p>\n<p>This manufacturing network is positioned to support the anticipated commercial launch of Cu-64 SAR-bisPSMA following the completion of Phase III trials (AMPLIFY and CLARIFY) and pending FDA New Drug Application approval. The commercial contract took effect on April 14, 2026, the day prior to the stock's movement.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CU6.AU","symbol_name":"CLARITY PHARMACEUTICALS LTD","start_time":0,"source_url":"","article_id":"1184551801","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1184551801","pubTimestamp":1776211595,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Clarity Pharmaceuticals Ltd (CU6.AU) saw its stock price soar 5.15% during intraday trading on Wednesday, following the announcement of a significant commercial manufacturing agreement. The company...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CU6.AU":"CLARITY PHARMACEUTICALS LTD"},"translate_title":"个股追踪|Clarity Pharmaceuticals盘中大涨5.15%CU-64 SAR-BiPSMA商业制造交易","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CU6.AU":1},"content_text":"Clarity Pharmaceuticals Ltd (CU6.AU) saw its stock price soar 5.15% during intraday trading on Wednesday, following the announcement of a significant commercial manufacturing agreement.\nThe company signed a deal with Nucleus RadioPharma for the manufacturing of Cu-64 SAR-bisPSMA. The agreement covers Nucleus's facility in Rochester, Minnesota, which has a capacity of approximately 50,000 patient doses per year. It also includes a planned site in Spring House, Pennsylvania, targeted to open in 2028 with a capacity of up to 600,000 doses per year.\nThis manufacturing network is positioned to support the anticipated commercial launch of Cu-64 SAR-bisPSMA following the completion of Phase III trials (AMPLIFY and CLARIFY) and pending FDA New Drug Application approval. The commercial contract took effect on April 14, 2026, the day prior to the stock's movement.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}